Is Tislelizumab a PD-1 or PD-L1 inhibitor?

Tislelizumab (Tislelizumab) is a monoclonal antibody drug targeting the programmed death receptor 1 (PD-1). It belongs to the immune checkpoint inhibitor class of drugs. It plays an anti-tumor effect by blocking the combination of PD-1 and its ligands PD-L1 and PD-L2, releasing the suppression of the immune system by tumor cells, and promoting T cell activation and immune response. It is clear that tislelizumab is a PD-1 inhibitor, which is helpful to understand its mechanism of action and clinical application.

PD-1 is an immune checkpoint receptor expressed on the surface of T cells. It is involved in regulating the tolerance of the immune system and preventing autoimmune reactions. Tumor cells express PD-L1 and combine with PD-1 to inhibit T cell function and allow immune escape. Tislelizumab blocks this immunosuppressive pathway by blocking PD-1 and restores the immune system's recognition and attack of tumors. It is a typical PD-1 inhibitor.

Different from PD-1 inhibitors, PD-L1 inhibitors directly block the PD-L1 molecules on the surface of tumor cells or other immune cells, blocking their binding to PD-1. The two classes of drugs differ in their mechanisms, but both are designed to activate the immune system's attack on cancer. As a PD-1 inhibitor, tislelizumab is one of the important drugs that relieves the immune "brake" mechanism. It has been approved for use in a variety of tumors such as non-small cell lung cancer and Hodgkin lymphoma.

In general, tislelizumab is clearly positioned as a PD-1 inhibitor that enhances the body's immune response to tumors by blocking the interaction between PD-1 and PD-L1/PD-L2. Understanding this is of great significance for the rational selection of immunotherapy regimens, predicting efficacy, and managing adverse reactions.

Reference materials:https://www.drugs.com/